Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine and Pemetrexed vs Paclitaxel and Gemcitabine in Advanced NSCLC
NCT00434135Phase 2Completed
- Sponsor
- Southern Italy Cooperative Oncology Group
- Start
- May 2006
- Primary completion
- Oct 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pemetrexed in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Southern Italy Cooperative Oncology Group. Primary endpoint: Response rate of patients treated with the gemcitabine plus Alimta regimen. Started May 2006; status: completed.
02
Drugs
pemetrexed
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00434135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00434135.